Identification of patients for breast cancer therapy
The invention relates to methods of detecting or monitoring breast cancer in a subject, or identifying the prognosis of a subject with breast cancer comprising determining the level and/or position of the expression of a T128 family, and optionally one or both of ER and HER2 in a sample.
A series of patients with primary early stage breast cancer were investigated for the expression of a novel candidate antigen identified by the JvGCRC labs and designated T128. The protein sequence revealed 100% sequence homology with a gene named PRPF38B which is a pre-mRNA splicing factor. T128 is believed to be an isoform of PRPF38B.
The applicants report on data associated with potential clinical and economical benefits of screening ER-/HER2+ breast cancer patients for T128 prior to the administration of Trastuzumab. They demonstrate that this screening will enable the clinicians to stratify more accurately a cohort of patients who would gain maximal clinical benefit from being treated with Trastuzumab, thus reducing the costs associated with this treatment while concurrently increasing the success rate of a well-known and established breast cancer treatment.
Benefits and applications
- Ability to stratify breast cancer patients more accurately for Trastuzumab treatment in order to gain maximal clinical benefit and increase the success rate of the therapy.
Professor R C Rees
The John Van Geest Cancer Research Centre